FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...
The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...
In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...
Your device does not support the audio. O’FALLON, Ill. — HSHS St. Elizabeth’s Hospital is proud to announce the 100th Aquablation therapy procedure, marking a significant milestone in the advancement ...
(UroToday.com) The 2024 ASTRO annual meeting included a session on optimizing the therapeutic ratio in prostate cancer, featuring a presentation by Dr. William Hall discussing dose-escalated pelvic ...
Feb. 12, 2026 8:30 AM ETProfound Medical Corp. (PROF), PRN:CA “We are deeply grateful to INOVAIT for supporting a vision where AI‑enabled, image‑guided therapies like TULSA-PRO are not only developed ...
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results